Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
China's surveyed urban unemployment rate rose to 5.3% in August, versus a 5.2% forecast and 5.2% previously.
2026-09-15
China's surveyed urban unemployment rate rose to 5.3% in August, versus a 5.2% forecast and 5.2% previously.
Back
Other News
2026-09-15
A U.S. federal judge in Boston on Sept. 14 enjoined the Department of Homeland Security from implementing a rule that would have capped how long foreign students and journalists may remain in the U.S. without applying for an extension; the rule was d
A U.S. federal judge in Boston on Sept. 14 enjoined the Department of Homeland Security from implementing a rule that would have capped how long foreign students and journalists may remain in the U.S. without applying for an extension; the rule was due to take effect Sept. 15. Judge Saylor said DHS’s stated rationale—citing national security and fraud prevention—was "extremely weak" and found the agency failed to meet legal obligations by not addressing concerns raised or considering less burdensome alternatives.
2026-09-14
Jiangsu Hengrui Medicine’s subsidiary Beijing Shengdi Pharmaceutical received an acceptance notice from the National Medical Products Administration (NMPA) for the marketing-authorisation application of SHR-2004 injection, a Class 1 innovative coagul
Jiangsu Hengrui Medicine’s subsidiary Beijing Shengdi Pharmaceutical received an acceptance notice from the National Medical Products Administration (NMPA) for the marketing-authorisation application of SHR-2004 injection, a Class 1 innovative coagulation factor XI (FXI) monoclonal antibody.
Chat with us
, powered by
LiveChat